Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Plast Reconstr Surg ; 129(4): 636e-645e, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22456377

ABSTRACT

BACKGROUND: The authors previously established an animal model of radiation-induced craniofacial bone growth inhibition and demonstrated the effectiveness of cytoprotection in preserving growth using amifostine, but the mechanism is unclear. The objective of this study was to investigate the acute and long-term histopathologic effects of single-dose orthovoltage irradiation on craniofacial bone with and without cytoprotection. METHODS: Sixty infant New Zealand White rabbits (7-week-old) were randomized into three groups (n = 20 per group): group 1, 0-Gy, sham irradiation; group 2, 35-Gy single-dose orthovoltage irradiation; and group 3, cytoprotection with amifostine before irradiation. Orbitozygomatic complex bone was harvested from animals 12 hours after irradiation and at skeletal maturity (21 weeks of age). Histologic parameters measured included native bone cell (osteoblast, osteoclast, and osteocyte) populations, periosteal proliferation indices (MIB-1 stains), bone turnover rates [triple fluorochromes: tetracycline administered at 7 weeks of age (before irradiation), alizarin complexone at 12 weeks, and calcein at 16 weeks of age], and endosteal space fibrosis levels. RESULTS: Orthovoltage irradiation significantly (p < 0.05) reduced osteoblast and osteoclast counts 12 hours after irradiation (age, 7 weeks) with or without pretreatment with amifostine but had no effect on osteocyte populations. Long-term analysis at age 21 weeks demonstrated significantly (p < 0.05) increased osteoblast counts, reduced endosteal space fibrosis, reduced periosteal proliferation indices, and improved bone turnover (fluorochrome stains) in amifostine-treated animals. CONCLUSION: This study suggests that amifostine cytoprotection is mediated through a combination of reduced cellular injury with enhanced promotion of cellular bone rebuilding potential.


Subject(s)
Amifostine/pharmacology , Orbit/growth & development , Orbit/radiation effects , Radiation-Protective Agents/pharmacology , Zygoma/growth & development , Zygoma/radiation effects , Animals , Bone Remodeling , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Dose-Response Relationship, Radiation , Ki-67 Antigen/analysis , Male , Orbit/drug effects , Orbit/pathology , Osteoblasts/drug effects , Osteoblasts/pathology , Osteoblasts/radiation effects , Periosteum/metabolism , Periosteum/pathology , Rabbits , Radiation Dosage , Zygoma/drug effects , Zygoma/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...